Published in TB and Outbreaks Week, February 29th, 2000
J. Lenhard and associates from Glaxo Wellcome Inc., in North Carolina, fed either high- or low-fat diets to obesity-prone (AKR/J) and resistant (SWR/J) mice. The diets were either treated with 2.9 mg/d of indinavir (IDV), nelfinavir (NFV), saquinavir (SQV), or amprenavir (APV). The researchers used subcutaneous infusion to deliver the treatments for 2 weeks and then determined metabolic and clinical toxicology markers.
The results of the study were presented at 7th Conference on Retroviruses and Opportunistic...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week